Roche Says Kadcyla Fails To Better Herceptin In First-Line Breast Cancer

Sales estimates for Roche’s Kadcyla will be cut sharply after news the MARIANNE study didn’t show the antibody-drug conjugate performing better than Herceptin in treating first-line breast cancer.